DPP-4抑制剂:不仅仅是一种降糖药
Dipeptidyl peptidase-4 inhibitors:more than an anti-hyperglycemia agent
摘要
二肽基肽酶4(DPP-4)抑制剂是一类新型口服降糖药物,主要通过提高胰高血糖素样肽-1(GLP-1)浓度刺激胰岛素、抑制胰高糖素分泌而控制糖尿病患者血糖,临床应用越来越广泛。除降糖作用之外,DPP-4抑制剂还显现出调节炎症反应、降低心血管危险因素、促进伤口愈合以及改善阿尔茨海默病等降糖外作用。
出处
《药品评价》
CAS
2014年第7期26-28,35,共4页
Drug Evaluation
参考文献18
-
1Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis[J]. Circulation, 2011, 124(21): 2338-2349. 被引量：1
-
2Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice[J]. Diabetes, 2011, 60(4): 1246-1257. 被引量：1
-
3Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients[J]. Metabolism, 2013, 62(3): 347-351. 被引量：1
-
4Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotie lesion formation in apolipoprotein E-deficient mice[J]. J Am Coll Cardiol, 2012, 59(3): 265-276. 被引量：1
-
5Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes[J]. Circ J, 2013, 77(5): 1337-1344. 被引量：1
-
6Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice[J]. J Cardiovasc Pharmacol, 2011, 58(2): 157-166. 被引量：1
-
7Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice[J1. Endocrinology, 2013, 154(3 ): 1260-1270. 被引量：1
-
8Patil HR, Al Badarin F J, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus[J]. Am J Cardiol, 2012, 110(6): 826-833. 被引量：1
-
9White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J]. N Engl J Med, 2013, 369(14): 1327-1335. 被引量：1
-
10Schurmann C, Linke A, Engelmann-Pilger K, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice[J]. J Pharmacol Exp Ther, 2012, 342(1): 71-80. 被引量：1
-
1杨迪,叶山东.二甲双胍降糖外作用的研究进展[J].国际病理科学与临床杂志,2013,33(6):553-557. 被引量：7
-
2林小波,田明,常伟平.急腹症合并糖尿病的围手术期处理[J].中国厂矿医学,2007,20(4):363-364. 被引量：2
-
3孙婷婷,陈福琴.口服降糖药的降糖外作用研究进展[J].中国老年学杂志,2009,29(12):1584-1587.
-
4刘超,徐书杭,陈国芳.二甲双胍的降糖外作用[J].临床药物治疗杂志,2013,11(1):8-11. 被引量：12
-
5黎艳,王意娟,黄守春,唐丽燕,于绍斌.强化健康教育对老年糖尿病足患者预后的影响[J].成都医学院学报,2012,7(B09):316-317.
-
6刘超,李春睿,徐书杭.二甲双胍对甲状腺疾病的影响及其临床处理[J].药品评价,2015,0(9):40-44. 被引量：1
-
7于凤枝.康复新治疗糖尿病足的临床疗效[J].浙江临床医学,2010,12(10):1101-1102.
-
8邓利娟,罗华山,吴豫梅,吴永新,林霖.自体骨髓干细胞移植治疗糖尿病足的效果观察[J].中国当代医药,2014,21(20):33-34. 被引量：5
-
9陈英.糖尿病足的护理体会[J].当代护士（下旬刊）,2013,20(6):33-34. 被引量：3
-
10刘璠,冯红云,杨爱格,王丽娜,周慧敏,尹婉宜.罗格列酮对糖调节受损患者红细胞变形能力及炎症因子的影响[J].现代中西医结合杂志,2014,23(14):1489-1491. 被引量：4
